This video introduces Touchlight’s state-of-the-art DNA manufacturing facility, located in the historic Morelands Waterworks in Hampton. Once a vital site for Victorian London’s clean water supply, it has been transformed…
Read More
In this webinar, Touchlight’s Elena Stoyanova, PhD introduces the company’s innovative DNA manufacturing technologies, focusing on their proprietary dbDNA™ (Doggybone DNA) and the newly developed mbDNA™ (MegaBulb DNA ). She…
Read More
Learn how doggybone DNA (dbDNA™) vaccines offer a safe, scalable alternative to plasmid DNA for cancer immunotherapy, delivering strong immune responses without bacterial components. Download the full article to learn:…
Read More
This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA™ platform. By incorporating neuraminidase (NA) alongside haemagglutinin (HA) and leveraging DNA targeting sequences (DTS),…
Read More
This article explores how Touchlight’s enzymatically amplified linear dbDNA™ technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector (LVV) manufacturing. By optimizing vector design and transfection conditions, the…
Read More
This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as "Doggybones." These linear constructs, which exclude unnecessary bacterial elements, demonstrated…
Read More
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
Read More
Recombinant AAV is a powerful vector for gene delivery—but its full potential is held back by the limitations of plasmid DNA. Touchlight’s whitepaper explores how dbDNA™, a synthetic, enzymatically produced…
Read More
Discover how synthetic, backbone-free DNA offers a safer, scalable alternative to traditional plasmid DNA for AAV production, addressing key challenges in transfection efficiency, cost, and impurity control. Download the poster…
Read More
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
Read More
